Plasmodium falciparum and Plasmodium vivax genotypes and efficacy of intermittent preventive treatment in Papua New Guinea

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6958-6961

  Barnadas, Celine ^a,b,c   Senn, Nicolas ^a,d   Iga, Jonah ^a   Timinao, Lincoln ^a   Javati, Sarah ^a   Malau, Elisheba ^a,b   Rarau, Patricia ^a   Reeder, John C ^e   Siba, Peter ^a   Karunajeewa, Harin ^b,c   Zimmerman, Peter A ^f   Davis, Timothy M ^g   Mueller, Ivo ^b,c,h  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e BURNET INSTITUTE   (Australia)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h Centre de Recerca en Salut Internacional de Barcelona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; GENOTYPE; MUTANT; NONHUMAN; PAPUA NEW GUINEA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PROGRAM EFFICACY; WILD TYPE; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETIC MARKER; GENETICS; HUMAN; INFANT; MALARIA, FALCIPARUM; MALARIA, VIVAX; PARASITOLOGY;

ANTIMALARIAL AGENT; CARRIER PROTEIN; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATION; GENETIC MARKER; MDR1 PROTEIN, PLASMODIUM FALCIPARUM; MULTIDRUG RESISTANCE PROTEIN; PFCRT PROTEIN, PLASMODIUM FALCIPARUM; PROTOZOAL PROTEIN;

ANTIMALARIALS; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; GENETIC MARKERS; GENOTYPE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALARIA, VIVAX; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PAPUA NEW GUINEA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84908432772     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03323-14     Document Type: Article

References (25)

1. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, Alonso P, Menendez C. 2009. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374:1533-1542. http://dx.doi.org/10.1016/S0140-6736(09)61258-7.
2. Gosling RD, Cairns ME, Chico RM, Chandramohan D. 2010. Intermittent preventive treatment against malaria: an update. Expert Rev. Anti Infect. Ther. 8:589-606. http://dx.doi.org/10.1586/eri.10.36.
3. de Pecoulas PE, Basco LK, Tahar R, Ouatas T, Mazabraud A. 1998. Analysis of the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene sequence. Gene 211:177-185. http://dx.doi.org/10.1016/S0378-1119(98)00118-8.
4. de Pecoulas PE, Tahar R, Ouatas T, Mazabraud A, Basco LK. 1998. Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol. Biochem. Parasitol. 92:265-273. http://dx.doi.org/10.1016/S0166-6851(97)00247-8.
5. Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K, Cheng Q. 2004. Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob. Agents Chemother. 48:2214-2222. http://dx.doi.org/10.1128/AAC.48.6.2214-2222.2004.
6. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM. 2001. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 17:582-588. http://dx.doi.org/10.1016/S1471-4922(01)02085-2.
7. Sidhu AB, Verdier-Pinard D, Fidock DA. 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298:210-213. http://dx.doi.org/10.1126/science.1074045.
8. Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, Sutanto I, Peyron F, Picot S. 2005. Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. J. Infect. Dis. 191:272-277. http://dx.doi.org/10.1086/426830.
9. Sá JM, Nomura T, Neves J, Baird JK, Wellems TE, del Portillo HA. 2005. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp. Parasitol. 109:256-259. http://dx.doi.org/10.1016/j.exppara.2004.12.005.
10. Barnadas C, Ratsimbasoa A, Tichit M, Bouchier C, Jahevitra M, Picot S, Menard D. 2008. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob. Agents Chemother. 52:4233-4240. http://dx.doi.org/10.1128/AAC.00578-08.
11. Griffin JT, Cairns M, Ghani AC, Roper C, Schellenberg D, Carneiro I, Newman RD, Grobusch MP, Greenwood B, Chandramohan D, Gosling RD. 2010. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS One 5:e12618. http://dx.doi.org/10.1371/journal.pone.0012618.
12. Venkatesan M, Alifrangis M, Roper C, Plowe CV. 2013. Monitoring antifolate resistance in intermittent preventive therapy for malaria. Trends Parasitol. 29:497-504. http://dx.doi.org/10.1016/j.pt.2013.07.008.
13. Marks F, von Kalckreuth V, Kobbe R, Adjei S, Adjei O, Horstmann RD, Meyer CG, May J. 2005. Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine. J. Infect. Dis. 192:1962-1965. http://dx.doi.org/10.1086/497698.
14. Senn N, Rarau P, Stanisic DI, Robinson L, Barnadas C, Manong D, Salib M, Iga J, Tarongka N, Ley S, Rosanas-Urgell A, Aponte JJ, Zimmerman PA, Beeson JG, Schofield L, Siba P, Rogerson SJ, Reeder JC, Mueller I. 2012. Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial. PLoS Med. 9:e1001195. http://dx.doi.org/10.1371/journal.pmed.1001195.
15. Barnadas C, Kent D, Timinao L, Iga J, Gray LR, Siba P, Mueller I, Thomas PJ, Zimmerman PA. 2011. A new high-throughput method for simultaneous detection of drug resistance associated mutations in Plasmodium vivax dhfr, dhps and mdr1 genes. Malar. J. 10:282. http://dx.doi.org/10.1186/1475-2875-10-282.
16. Carnevale EP, Kouri D, DaRe JT, McNamara DT, Mueller I, Zimmerman PA. 2007. A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance. J. Clin. Microbiol. 45:752-761. http://dx.doi.org/10.1128/JCM.01683-06.
17. Wong RP, Karunajeewa H, Mueller I, Siba P, Zimmerman PA, Davis TM. 2011. Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in Papua New Guinea using an extended ligase detection reaction fluorescent microsphere assay. Antimicrob. Agents Chemother. 55:798-805. http://dx.doi.org/10.1128/AAC.00939-10.
18. DaRe JT, Kouri DP, Zimmerman PA, Thomas PJ. 2010. Differentiating Plasmodium falciparum alleles by transforming Cartesian X,Y data to polar coordinates. BMC Genet. 11:57. http://dx.doi.org/10.1186/1471-2350-11-57.
19. Marfurt J, Muller I, Sie A, Oa O, Reeder JC, Smith TA, Beck HP, Genton B. 2008. The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea. Malar. J. 7:61. http://dx.doi.org/10.1186/1475-2875-7-61.
20. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. 2009. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar. J. 8:89. http://dx.doi.org/10.1186/1475-2875-8-89.
21. Lynch C, Pearce R, Pota H, Cox J, Abeku TA, Rwakimari J, Naidoo I, Tibenderana J, Roper C. 2008. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. J. Infect. Dis. 197:1598-1604. http://dx.doi.org/10.1086/587845.
22. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ, Sibley CH, Baird JK. 2004. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J. Infect. Dis. 189:744-750. http://dx.doi.org/10.1086/381397.
23. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. 2002. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob. Agents Chemother. 46:3947-3953. http://dx.doi.org/10.1128/AAC.46.12.3947-3953.2002.
24. Mayor A, Serra-Casas E, Sanz S, Aponte JJ, Macete E, Mandomando I, Puyol L, Berzosa P, Dobano C, Aide P, Sacarlal J, Benito A, Alonso P, Menendez C. 2008. Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J. Infect. Dis. 197:1737-1742. http://dx.doi.org/10.1086/588144.
25. World Health Organization. 2010. Policy recommendation on intermittent preventive treatment during infancy with sulphadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa. World Health Organization, Geneva, Switzerland.